KannaLife

Kannalife Sciences Inc. is a bio-pharmaceutical and phyto-medical company based in Doylestown, Pennsylvania founded by Dean Petkanas and Thoma Kikis.[1] Kannalife was formed in 2010 and is involved in the research and development of novel new therapeutic agents designed to reduce oxidative stress, and act as immuno-modulators and neuroprotectants.[2]

KannaLife Sciences Inc.
Private
IndustryPharmaceutical
Founded2010
FoundersDean Petkanas, Thoma Kikis
HeadquartersDoylestown, Pennsylvania
Total assetsExclusive License of patent US 6630507
Websitehttp://kannalife.com
KannaLife was granted the Exclusive License by NIH-OTT for the commercialization of patent US 6630507 “Cannabinoids as Antioxidants and Neuroprotectants."

In 2011, the company was granted an Exclusive License[3] by National Institutes of Health – Office of Technology Transfer (NIH-OTT) for the Commercialization of patent US 6630507, “Cannabinoids as Antioxidants and Neuroprotectants."[4]

Kannalife is currently conducting research and development at the Pennsylvania Biotechnology Center of Bucks County[5] in Doylestown, PA, for a target drug candidate, KLS-13019[6] to treat Hepatic encephalopathy and CTE,[7] an oxidative stress related disease that affects the cognitive and behavioral functions, and the wellness of the brain.

Kannalife was featured in Sports Illustrated article on using cannabinoids to treat CTE. [8]

References
  1. Guion, Payton (November 12, 2014). "The NFL's Anti-Weed Policy Even Extends to Drugs That Could Prevent Brain Damage". VICE News. Archived from the original on May 8, 2015. Retrieved 2014-12-12.
  2. Leland, John (October 31, 2014). "For Pot Inc., the Rush to Cash In Is Underway". The New York Times. Retrieved 2014-10-31.
  3. "Prospective Grant of Exclusive License: Development of Cannabinoid(s) and Cannabidiol(s) Based Therapeutics To Treat Hepatic Encephalopathy in Humans". federalregister.gov. Retrieved 2011-11-17.
  4. "Kannalife Sciences, Inc. Signs Exclusive License Agreement With National Institutes Of Health Office Of Technology Transfer (NIH-OTT)". thestreet.com. Retrieved 2012-07-09.
  5. "Kannalife in R&D Collaboration for Cannabinoid-Based Drugs". Genengnews.com. Retrieved 2013-04-04.
  6. William A. Kinney; Mark E. McDonnell; Hua Marlon Zhong; Chaomin Liu; Lanyi Yang; Wei Ling; Tao Qian; Yu Chen; Zhijie Cai; Dean Petkanas; Douglas E. Brenneman. "Discovery of KLS-13019, a Cannabidiol-Derived Neuroprotective Agent, with Improved Potency, Safety, and Permeability". ACS Med. Chem. Lett. doi:10.1021/acsmedchemlett.6b00009. PMC 4834656.
  7. Mulvihill Moran, Jessica (November 9, 2014). "Medical marijuana company developing drug to protect NFL players' brains". Fox News. Retrieved 2014-11-09.
  8. "How cannabis is helping one company research treatment of CTE". Sports Illustrated. July 12, 2016.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.